NCT02553915View on ClinicalTrials.gov

Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 13, 2018

Study Completion Date

March 31, 2022

Conditions
Major Depressive DisorderOverweightInflammation
Interventions
OTHER

Placebo

Soybean oil placebo

DRUG

EPA 1 g/day

Omega-3 fatty acid extracted from fish oil, 1 g/day

DRUG

EPA 2 g/day

Omega-3 fatty acid extracted from fish oil, 2 g/day

DRUG

EPA 4 g/day

Omega-3 fatty acid extracted from fish oil, 4 g/day

Trial Locations (2)

30322

Emory University School of Medicine, Atlanta

02114

Depression Clinical and Research Program at Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Emory University

OTHER

lead

Massachusetts General Hospital

OTHER

NCT02553915 - Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach | Biotech Hunter | Biotech Hunter